Astrazeneca plc - ADR
AZN
Market Cap$229.56B
Close$
Earnings Call Q1 2025
April 29, 2025 - AI Summary
Strong Revenue Growth: AstraZeneca reported a total revenue growth of 10% in Q1 2025, with product sales increasing by 9%. Core operating profit rose by 12%, and core earnings per share (EPS) increased by 21%, aided by a lower tax rate due to settlements in certain jurisdictions.
Pipeline Development & Approvals: The company secured 13 approvals across key regions since February, with five positive Phase III results announced in recent months. AstraZeneca has set a goal to deliver at least 20 new medicines by 2030, having already approved nine, highlighting a robust pipeline that could drive future revenue growth.
Oncology & Hematology Performance: The Oncology business saw total revenues grow by 13% in Q1 to $5.6 billion, with strong performances from key products like Tagrisso and Calquence. Demand dynamics from Medicare Part D redesign began affecting performance, but volume growth is expected to continue supporting revenue in the sector.
Exclusive for Stockcircle Pro members
Sign up
$39.06
47.5% downside
Current Fair Value
47.5% downsideOvervalued by 47.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $229.56 Billion |
|---|---|
| Enterprise Value | $255.28 Billion |
| Dividend Yield | $1.54 (1.29958060177502%) |
| Earnings per Share | $1.14 |
| Beta | 0.17 |
| Outstanding Shares | 6,200,000,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 29.73 |
|---|---|
| PEG | 79.82 |
| Price to Sales | 9.3 |
| Price to Book Ratio | 12.4 |
| Enterprise Value to Revenue | 4.64 |
| Enterprise Value to EBIT | 23.26 |
| Enterprise Value to Net Income | 32 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.75 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About AstraZeneca Plc
CEO: Pascal Soriot AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...